

Andreas Obermair

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8233897/publications.pdf>

Version: 2024-02-01

230
papers

10,132
citations

31976

53
h-index

46799

89
g-index

237
all docs

237
docs citations

237
times ranked

8695
citing authors

#	ARTICLE	IF	CITATIONS
1	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 33, 560-565.	2.5	4
2	Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100914.	0.6	3
3	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj ETQq1 1 0.784314 rgBTj Overlo	1.4	2
4	Vaginal vault smear cytology in detection of recurrence after hysterectomy for early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003302.	2.5	0
5	Germline BRCA variants, lifestyle and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2022, , .	1.4	2
6	Are endometrial cancer clinical practice management guidelines sufficiently consumer centric?. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003580.	2.5	0
7	Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles. <i>Journal of Clinical Oncology</i> , 2022, 40, 2378-2388.	1.6	3
8	Development and validation of a recommended checklist for assessment of surgical videos quality: the LAParoscopic surgery Video Educational GuidelineS (LAP-VEGaS) video assessment tool. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1362-1369.	2.4	38
9	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
10	Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. <i>Gynecologic Oncology</i> , 2021, 161, 143-151.	1.4	46
11	Paucity of data evaluating patient centred outcomes following sentinel lymph node dissection in endometrial cancer: A systematic review. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100763.	0.6	8
12	Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study). <i>Cancers</i> , 2021, 13, 2378.	3.7	3
13	Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review. <i>Cancers</i> , 2021, 13, 4608.	3.7	25
14	Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 553-561.	2.5	11
15	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.	2.2	5
16	Long-term quality of life outcomes of women treated for early-stage endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 530-536.	2.5	14
17	A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer â€” ENDO-3: ANZGOG trial 1911/2020. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1595-1601.	2.5	20
18	Fertility-sparing management of early-stage endometrial cancer in reproductive age women: current treatment outcomes and future directions. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1506-1507.	2.5	3

#	ARTICLE	IF	CITATIONS
19	The impact of team familiarity on surgical outcomes in gynaecological surgery. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 290-292.	0.9	5
20	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 249.e1-249.e10.	1.3	78
21	Patient-Reported Experiences After Hysterectomy: A Cross-Sectional Study of the Views of Over 2300 Women. <i>Journal of Patient Experience</i> , 2020, 7, 372-379.	0.9	9
22	A Bioimpedance Spectroscopy-Based Method for Diagnosis of Lower-Limb Lymphedema. <i>Lymphatic Research and Biology</i> , 2020, 18, 101-109.	1.1	13
23	Can a symptom checklist improve the triage of patients following successful endometrial cancer treatment?. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100604.	0.6	0
24	Quality of life following minimally invasive hysterectomy compared to abdominal hysterectomy: A meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 206-212.	1.1	10
25	Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1935-1942.	2.5	15
26	Physical activity trajectories following gynecological cancer: results from a prospective, longitudinal cohort study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1784-1790.	2.5	11
27	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 179-186.	1.4	20
28	Sentinel lymph node mapping in endometrial cancer – areas where further research is needed. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 283-284.	2.5	15
29	Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. <i>Gynecologic Oncology</i> , 2020, 158, 47-53.	1.4	6
30	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1240-1250.	1.2	85
31	Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study.. <i>Gynecologic Oncology</i> , 2020, 158, 375-381.	1.4	18
32	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2020, 21, 851-860.	10.7	57
33	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	2.5	21
34	A healthy lifestyle and survival among women with ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 3361-3369.	5.1	16
35	The use of CAM products, practices, and practitioners by long-term endometrial cancer survivors in Australia. <i>Supportive Care in Cancer</i> , 2020, 28, 5479-5489.	2.2	5
36	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 417-431.	1.6	48

#	ARTICLE	IF	CITATIONS
37	Obesity in total laparoscopic hysterectomy for early stage endometrial cancer: health gain and inpatient resource use. <i>International Journal for Quality in Health Care</i> , 2019, 31, 283-288.	1.8	3
38	Incidence of adverse events, preventability and mortality in gynaecological hospital admissions: A systematic review and meta-analysis. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 195-200.	1.0	7
39	How to train practising gynaecologists in total laparoscopic hysterectomy: protocol for the stepped-wedge IMAGINE trial. <i>BMJ Open</i> , 2019, 9, e027155.	1.9	10
40	Anxiety and depression in patients with early stage endometrial cancer: A longitudinal analysis from before surgery to 6-month post-surgery. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2019, 1, e13.	0.5	6
41	Challenges and controversies in the conservative management of uterine and ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 55, 93-108.	2.8	9
42	How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?. <i>Gynecologic Oncology</i> , 2019, 152, 339-345.	1.4	5
43	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
44	LAP-VEGaS Practice Guidelines for Reporting of Educational Videos in Laparoscopic Surgery. <i>Annals of Surgery</i> , 2018, 268, 920-926.	4.2	93
45	All-cause death in young women with endometrial cancer who receive progesterone therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 119.	1.3	0
46	Disease-Free and Survival Outcomes for Total Laparoscopic Hysterectomy Compared With Total Abdominal Hysterectomy in Early-Stage Endometrial Carcinoma: A Meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 529-538.	2.5	28
47	Pelvic floor functional outcomes after total abdominal vs total laparoscopic hysterectomy for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 419.e1-419.e14.	1.3	7
48	The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 99-105.	1.4	49
49	Factors influencing women's decision making in hysterectomy. <i>Patient Education and Counseling</i> , 2018, 101, 504-510.	2.2	6
50	ER and PR expression and survival after endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 258-266.	1.4	49
51	The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer. <i>Rehabilitation Oncology</i> , 2018, 36, 48-55.	0.5	6
52	Normative Interlimb Impedance Ratios: Implications for Early Diagnosis of Uni- and Bilateral, Upper and Lower Limb Lymphedema. <i>Lymphatic Research and Biology</i> , 2018, 16, 559-566.	1.1	9
53	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1895-1904.	27.0	1,274
54	Surgical approach to hysterectomy and barriers to using minimally invasive methods. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2018, 58, 690-695.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Endometrial cancer risk and survival by tumor MMR status. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e39.	2.2	34
56	Do breast cancer survivors benefit from prophylactic removal of uterus and ovaries? A population-based data linkage replication study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 68-78.	1.1	3
57	Nutrition interventions in patients with gynecological cancers requiring surgery. <i>Gynecologic Oncology</i> , 2017, 145, 192-199.	1.4	35
58	Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. <i>Gynecologic Oncology</i> , 2017, 146, 623-629.	1.4	92
59	Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1224.	7.4	271
60	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. <i>Gynecologic Oncology</i> , 2017, 147, 381-387.	1.4	30
61	The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 651-658.	1.0	16
62	Survival After Laparoscopic vs Abdominal Hysterectomy—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 574.	7.4	0
63	The relative risk of second primary cancers in Austria—The western states: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 699.	2.6	12
64	Real-world surgical outcomes of a gelatin hemostatic matrix in women requiring a hysterectomy: a matched case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 1008-1014.	2.8	5
65	Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 1.	3.6	25
66	Cost-Efficiency of Robotic Surgery. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 992-993.	2.5	1
67	Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 136, 87-93.	1.4	100
68	Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. <i>BMC Cancer</i> , 2015, 15, 33.	2.6	41
69	Consideration for safe and effective gynaecological laparoscopy in the obese patient. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 135-141.	1.7	13
70	Quality of life after early enteral feeding versus standard care for proven or suspected advanced epithelial ovarian cancer: Results from a randomised trial. <i>Gynecologic Oncology</i> , 2015, 137, 516-522.	1.4	13
71	Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: Results from the LACE trial. <i>Gynecologic Oncology</i> , 2015, 137, 102-105.	1.4	13
72	Incidence, Risk Factors, and Estimates of a Woman's Risk for Developing Secondary Lower Limb Lymphedema and Lymphedema-Specific Supportive Care Needs in Women Treated for Endometrial Cancer. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 176-177.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Women with self-reported lower-limb lymphedema after treatment for gynecological cancers: are they more likely to self-report psychosocial symptoms and less likely to use services?. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 55-61.	0.1	4
74	The Lymphedema Evaluation in Gynecological cancer Study (LEGS): design of a prospective, longitudinal, cohort study. <i>Cancer Research Frontiers</i> , 2015, 1, 104-118.	0.2	11
75	Knowledge, Attitudes and Referral Patterns of Lynch Syndrome: A Survey of Clinicians in Australia. <i>Journal of Personalized Medicine</i> , 2014, 4, 218-244.	2.5	9
76	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , 2014, 201, 283-288.	1.7	56
77	Reply to J. Moline et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 2278-2279.	1.6	5
78	Comment on "External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours". <i>British Journal of Cancer</i> , 2014, 111, 2375-2375.	6.4	2
79	Can the use of quality assurance tools reduce the impact of surgical complications on the well-being of obstetricians and gynaecologists in Australia and New Zealand?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014, 54, 30-35.	1.0	1
80	Quality of life of women with lower limb swelling or lymphedema 3-5 years following endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 314-318.	1.4	56
81	Metastasis of ovarian cancer is mediated by kallikrein related peptidases. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 135-147.	3.3	47
82	The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer: A population-based data linkage study. <i>International Journal of Cancer</i> , 2014, 134, 2211-2222.	5.1	19
83	Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. <i>Journal of Clinical Oncology</i> , 2014, 32, 90-100.	1.6	195
84	Improving treatment for obese women with early stage cancer of the uterus: Rationale and design of the levonorgestrel intrauterine device±Metformin±weight loss in endometrial cancer (feMME) trial. <i>Contemporary Clinical Trials</i> , 2014, 39, 14-21.	1.8	58
85	Serum HE4 as a prognostic marker in endometrial cancer: A population based study. <i>Gynecologic Oncology</i> , 2014, 132, 159-165.	1.4	86
86	Vaginal cuff dehiscence associated with laparoscopic hysterectomy. <i>Gynecological Surgery</i> , 2013, 10, 227-227.	0.9	0
87	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. <i>International Journal of Cancer</i> , 2013, 132, 2876-2883.	5.1	26
88	Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumours using biomarkers or the ROMA algorithm. <i>Gynecologic Oncology</i> , 2013, 130, 400.	1.4	1
89	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer: A population-based study. <i>Gynecologic Oncology</i> , 2013, 129, 310-317.	1.4	30
90	A review of complications associated with the surgical treatment of vulvar cancer. <i>Gynecologic Oncology</i> , 2013, 131, 467-479.	1.4	98

#	ARTICLE	IF	CITATIONS
91	Epidural analgesia is associated with an increased incidence of postoperative complications in patients requiring an abdominal hysterectomy for early stage endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 131, 423-429.	1.4	20
92	Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: A case-control study, systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2013, 132, 1146-1155.	5.1	64
93	Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. <i>European Journal of Cancer</i> , 2013, 49, 2717-2726.	2.8	57
94	Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. <i>Gynecologic Oncology</i> , 2013, 129, 467-471.	1.4	39
95	Feasibility and Outcomes of Ureteroureterostomy and Extravesical Ureteroneocystostomy as Part of Radical Surgery for Infiltrating Gynecologic Disease. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1139-1145.	2.5	3
96	Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in Australia. <i>BMJ Quality and Safety</i> , 2013, 22, 878-878.	3.7	2
97	Endometrial polyp and endometriosis with atypical stromal cells. <i>Pathology</i> , 2013, 45, 191-193.	0.6	1
98	The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. <i>BMJ Open</i> , 2013, 3, e001884.	1.9	29
99	Differences in Epidural and Analgesic Use in Patients with Apparent Stage I Endometrial Cancer Treated by Open versus Laparoscopic Surgery: Results from the Randomised LACE Trial. <i>Minimally Invasive Surgery</i> , 2013, 2013, 1-5.	0.5	7
100	Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors. <i>Psycho-Oncology</i> , 2013, 22, 1963-1971.	2.3	27
101	Nomogram to Predict the Probability of Relapse in Patients Diagnosed With Borderline Ovarian Tumors. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 264-267.	2.5	18
102	Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E305-E313.	3.5	14
103	Validation of the FIGO 2009 Staging System for Carcinoma of the Vulva. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 498-502.	2.5	30
104	Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. <i>Gynecologic Oncology</i> , 2012, 125, 520-525.	1.4	27
105	Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 1147-1153.	2.8	86
106	Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: Results from a randomised controlled trial. <i>European Journal of Cancer</i> , 2012, 48, 2155-2162.	2.8	33
107	The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2012, 5, 11.	3.0	5
108	The utility of serum CA125 in predicting extrauterine disease in apparent early-stage endometrial cancer. <i>International Journal of Cancer</i> , 2012, 131, 885-890.	5.1	35

#	ARTICLE	IF	CITATIONS
109	Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. <i>Gynecologic Oncology</i> , 2012, 125, 263-270.	1.4	124
110	Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801). <i>Gynecologic Oncology</i> , 2012, 126, 36-40.	1.4	28
111	Quality of life of women with lower-limb lymphedema following gynecological cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 287-297.	1.4	67
112	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 289-295.	2.5	239
113	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 179-184.	1.4	12
114	Hospital costs associated with adverse events in gynecological oncology. <i>Gynecologic Oncology</i> , 2011, 121, 70-75.	1.4	9
115	Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. <i>BMC Cancer</i> , 2011, 11, 389.	2.6	53
116	Clinical Audit in Gynecological Cancer Surgery: Development of a Risk Scoring System to Predict Adverse Events. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 93-94.	0.4	1
117	Evaluation of Tumor-Free Distance and Depth of Myometrial Invasion as Prognostic Factors for Lymph Node Metastases in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1217-1221.	2.5	23
118	Expression and In Vitro Functions of the Ghrelin Axis in Endometrial Cancer. <i>Hormones and Cancer</i> , 2010, 1, 245-255.	4.9	31
119	Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort study. <i>BMC Cancer</i> , 2010, 10, 232.	2.6	99
120	Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. <i>International Journal of Cancer</i> , 2010, 127, 2678-2684.	5.1	50
121	Potential hospital cost-savings attributed to improvements in outcomes for colorectal cancer surgery following self-audit. <i>BMC Surgery</i> , 2010, 10, 4.	1.3	6
122	Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 772-780.	10.7	296
123	Laparoscopy or laparotomy for early endometrial cancer? " Authors' reply. <i>Lancet Oncology</i> , The, 2010, 11, 1022-1023.	10.7	2
124	Advanced cytoreductive surgery: Asia Pacific perspective. <i>Gynecologic Oncology</i> , 2009, 114, S15-S21.	1.4	6
125	Clinical audit in gynecological cancer surgery: Development of a risk scoring system to predict adverse events. <i>Gynecologic Oncology</i> , 2009, 115, 329-333.	1.4	35
126	Survey of surgical skills of RANZCOG trainees. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009, 49, 84-92.	1.0	19

#	ARTICLE	IF	CITATIONS
127	Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2009, 49, 660-666.	1.0	22
128	Re: Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage1. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 447-447.	1.0	1
129	Elderly patients with stage III or IV ovarian cancer: should they receive standard care?. International Journal of Gynecological Cancer, 2008, 18, 896-907.	2.5	29
130	Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma. Gynecologic Oncology, 2008, 110, 280-285.	1.4	12
131	A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. Journal of Minimally Invasive Gynecology, 2008, 15, 584-588.	0.6	144
132	Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients. Clinical Cancer Research, 2008, 14, 1692-1700.	7.0	91
133	Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. American Journal of Clinical Nutrition, 2008, 87, 1678-1685.	4.7	144
134	Lynch Syndrome in Women Less Than 50 Years of Age With Endometrial Cancer. Obstetrics and Gynecology, 2008, 112, 943.	2.4	2
135	Lymphedema after gynecological cancer treatment. Cancer, 2007, 109, 2607-2614.	4.1	303
136	Malnutrition among gynaecological cancer patients. European Journal of Clinical Nutrition, 2007, 61, 642-646.	2.9	119
137	RANDOMIZED TRIAL OF SKIN CLOSURE AFTER LAPAROTOMY FOR GYNAECOLOGICAL SURGERY. ANZ Journal of Surgery, 2007, 77, 460-463.	0.7	13
138	Total laparoscopic hysterectomy: The Brisbane learning curve. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 65-69.	1.0	20
139	Laparoscopy in the treatment of ovarian tumours of low malignant potential. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 438-444.	1.0	8
140	Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 504-507.	1.0	31
141	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecologic Oncology, 2007, 104, 607-611.	1.4	29
142	Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecologic Oncology, 2007, 107, 124-129.	1.4	54
143	Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer. Gynecologic Oncology, 2007, 107, 357-358.	1.4	3
144	Total laparoscopic versus open surgery for stage 1 endometrial cancer: The LACE randomized controlled trial. Contemporary Clinical Trials, 2006, 27, 353-363.	1.8	67

#	ARTICLE	IF	CITATIONS
145	Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 319-324.	2.5	135
146	Postoperative analgesic requirements - total laparoscopic hysterectomy versus vaginal hysterectomy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 140-143.	1.0	23
147	Wrigley forceps to deliver a bulky uterus following a total laparoscopic hysterectomy for endometrial cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2005, 45, 444-445.	1.0	7
148	Vulval Keratoacanthoma: a case report. <i>Gynecologic Oncology</i> , 2005, 97, 674-676.	1.4	10
149	The functional assessment of cancer-vulvar: Reliability and validity. <i>Gynecologic Oncology</i> , 2005, 97, 568-575.	1.4	51
150	Small-cell carcinoma of the uterus and the vagina: experience with ten patients. <i>Archives of Gynecology and Obstetrics</i> , 2005, 271, 316-319.	1.7	24
151	Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 319-324.	2.5	110
152	Prognostic Importance of Preoperative CA-125 in International Federation of Gynecology and Obstetrics Stage I Epithelial Ovarian Cancer: An Australian Multicenter Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5938-5942.	1.6	71
153	Vulvar cancer patients' quality of life: a qualitative assessment. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 875-881.	2.5	95
154	Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2004, 92, 175-179.	1.4	24
155	Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. <i>Gynecologic Oncology</i> , 2004, 92, 789-793.	1.4	121
156	The overlay autogenous tissue (OAT) patch to control major intraoperative vascular injury in an ovine model. <i>Gynecologic Oncology</i> , 2004, 94, 560-563.	1.4	10
157	The control of severe intraoperative bleeding using an overlay autogenous tissue (OAT) patch: case reports. <i>Gynecologic Oncology</i> , 2004, 94, 564-566.	1.4	8
158	The anatomy of complications workshop: an educational strategy to improve the training and performance of fellows in gynecologic oncology. <i>Gynecologic Oncology</i> , 2004, 94, 769-773.	1.4	22
159	Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2004, 95, 701-705.	1.4	44
160	Impaired Quality of Life in Patients Commencing Radiotherapy for Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 78-83.	2.0	25
161	Erratum to "Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin vs cisplatin with cyclophosphamide-cisplatin". <i>European Journal of Cancer</i> , 2004, 40, 627.	2.8	0
162	Total Laparoscopic Hysterectomy with a Transvaginal Tube. <i>Journal of Minimally Invasive Gynecology</i> , 2004, 11, 79-82.	1.2	29

#	ARTICLE	IF	CITATIONS
163	Incidence of Anaemia in Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 347-353.	2.5	21
164	Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 633-639.	2.5	30
165	Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. <i>European Journal of Cancer</i> , 2003, 39, 1129-1140.	2.8	24
166	Feasibility and Safety of Total Laparoscopic Radical Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2003, 10, 345-349.	1.2	44
167	Histopathologic Correlation of High-Resolution Magnetic Resonance Imaging of Human Cervical Tissue Samples at 3 Tesla. <i>Investigative Radiology</i> , 2002, 37, 381-385.	6.2	2
168	The Urethra During Pelvic Floor Contraction. <i>Obstetrics and Gynecology</i> , 2002, 100, 796-800.	2.4	5
169	The urethra during pelvic floor contraction: observations on three-dimensional ultrasound. <i>Obstetrics and Gynecology</i> , 2002, 100, 796-800.	2.4	28
170	Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. <i>Cancer Letters</i> , 2002, 179, 197-203.	7.2	48
171	Expression of MUC1 splice variants in benign and malignant ovarian tumours. <i>International Journal of Cancer</i> , 2002, 100, 166-171.	5.1	42
172	Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. <i>International Journal of Cancer</i> , 2002, 102, 237-243.	5.1	80
173	The Western Australian Experience of the Use of en Bloc Resection of Ovarian Cancer with Concomitant Rectosigmoid Colectomy. <i>Gynecologic Oncology</i> , 2002, 84, 53-57.	1.4	57
174	The Impact of Positive Peritoneal Washings and Serosal and Adnexal Involvement on Survival in Patients with Stage IIIA Uterine Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 269-273.	1.4	26
175	Impact of Videotaped Information on Frequency and Confidence of Breast Self-Examination. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 37-43.	2.5	28
176	Increased microvessel density in adenomyosis uteri. <i>Fertility and Sterility</i> , 2001, 75, 131-135.	1.0	59
177	Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. <i>Cancer Letters</i> , 2001, 164, 105-110.	7.2	59
178	Primary fallopian tube carcinoma: the Queensland experience. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 69-72.	2.5	30
179	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors*. <i>Medical and Pediatric Oncology</i> , 2001, 36, 601-604.	1.0	59
180	Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma. <i>Cancer</i> , 2001, 92, 903-908.	4.1	72

#	ARTICLE	IF	CITATIONS
181	Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. <i>International Journal of Cancer</i> , 2001, 95, 29-33.	5.1	84
182	Prognostic Parameters in Endometrial Stromal Sarcoma: A Clinicopathologic Study in 31 Patients. <i>Gynecologic Oncology</i> , 2001, 81, 160-165.	1.4	109
183	Safety and Efficacy of Low Anterior en Bloc Resection as Part of Cytoreductive Surgery for Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 2001, 83, 115-120.	1.4	108
184	Novel MUC1 Splice Variants Are Expressed in Cervical Carcinoma. <i>Gynecologic Oncology</i> , 2001, 83, 343-347.	1.4	29
185	Primary Bartholin gland carcinoma: a report of seven cases. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2001, 41, 78-81.	1.0	29
186	Three-dimensional ultrasound of the female urethra: comparing transvaginal and transrectal scanning. <i>Ultrasound in Obstetrics and Gynecology</i> , 2001, 17, 425-430.	1.7	31
187	Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2001, 80, 432-436.	2.8	32
188	Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. <i>International Journal of Cancer</i> , 2001, 95, 29-33.	5.1	1
189	Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 77-78.	2.8	17
190	Quality of life changes during conformal radiation therapy for prostate carcinoma. <i>Cancer</i> , 2000, 89, 1322-1328.	4.1	83
191	Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. <i>British Journal of Haematology</i> , 2000, 110, 605-609.	2.5	32
192	Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 77-78.	2.8	7
193	Does hysteroscopy facilitate tumor cell dissemination?. <i>Cancer</i> , 2000, 88, 139-143.	4.1	5
194	Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 275-279.	2.5	34
195	Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer.. <i>Oncology Reports</i> , 2000, 7, 639-44.	2.6	29
196	Austrian women's attitudes toward and knowledge of breast self-examination. <i>Journal of Cancer Education</i> , 2000, 15, 91-4.	1.3	11
197	Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 383-386.	2.5	73
198	CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. <i>British Journal of Cancer</i> , 1999, 81, 662-666.	6.4	29

#	ARTICLE	IF	CITATIONS
199	Leiomyosarcoma of the Uterus: A Clinicopathologic Multicenter Study of 71 Cases. <i>Gynecologic Oncology</i> , 1999, 74, 196-201.	1.4	167
200	Serum Concentrations of Endostatin in Patients with Vulvar Cancer. <i>Gynecologic Oncology</i> , 1999, 74, 151-152.	1.4	28
201	Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. <i>Cancer Letters</i> , 1999, 138, 175-182.	7.2	44
202	Prognostic significance of tumor angiogenesis in primary fallopian tube cancer. <i>Cancer Letters</i> , 1999, 141, 179-186.	7.2	2
203	Expression of mucins and cytokeratins in ovarian cancer cell lines. <i>Cancer Letters</i> , 1999, 145, 133-141.	7.2	28
204	Prognostic significance of tumor angiogenesis in endometrial cancer. <i>Obstetrics and Gynecology</i> , 1999, 93, 367-371.	2.4	25
205	Vascular endothelial growth factor and its receptors in male fertility. <i>Fertility and Sterility</i> , 1999, 72, 269-275.	1.0	33
206	Correlation of the serum concentration of vascular endothelial growth factor (VEGF) and hemoglobin levels in patients with epithelial ovarian cancer. <i>Annals of Oncology</i> , 1999, 10, 998.	1.2	2
207	Comparison of flow cytometry and RT-PCR for the detection of ovarian cancer cells in peripheral blood. <i>Oncology Research</i> , 1999, 11, 367-73.	1.5	5
208	Color-coded and spectral Doppler flow in breast carcinomas – Relationship with the tumor microvasculature. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 83-89.	2.5	64
209	p53 Protein Overexpression: A Strong Prognostic Factor in Uterine Papillary Serous Carcinoma. <i>Gynecologic Oncology</i> , 1998, 71, 59-63.	1.4	29
210	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. <i>British Journal of Cancer</i> , 1998, 77, 1870-1874.	6.4	61
211	Tumor angiogenesis in stage IB cervical cancer: Correlation of microvessel density with survival. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 314-319.	1.3	95
212	The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma. , 1998, 82, 689-696.		21
213	The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. <i>Cancer</i> , 1998, 83, 726-731.	4.1	57
214	Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. <i>Cancer Letters</i> , 1998, 130, 69-76.	7.2	33
215	Vascular endothelial growth factor serum concentrations in ovarian cancer. <i>Obstetrics and Gynecology</i> , 1998, 92, 360-363.	2.4	82
216	Vascular Endothelial Growth Factor Serum Concentrations in Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 1998, 92, 360-363.	2.4	51

#	ARTICLE	IF	CITATIONS
217	The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. <i>Cancer</i> , 1998, 83, 726-31.	4.1	21
218	Correlation of Vascular Endothelial Growth Factor Expression and Microvessel Density in Cervical Intraepithelial Neoplasia. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1212-1217.	6.3	74
219	Parity as an Independent Prognostic Factor in Malignant Mixed Mesodermal Tumors of the Endometrium. <i>Gynecologic Oncology</i> , 1997, 64, 121-125.	1.4	19
220	Angiogenesis in Vulvar Intraepithelial Neoplasia. <i>Gynecologic Oncology</i> , 1997, 64, 496-500.	1.4	46
221	In vitro cytokine and prostaglandin production by amnion cells in the presence of bacteria. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 981-984.	1.3	15
222	Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. , 1997, 74, 455-458.		132
223	Influence of Microvessel Density and Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression on Prognosis in Vulvar Cancer. <i>Gynecologic Oncology</i> , 1996, 63, 204-209.	1.4	84
224	Influence of delayed diagnosis on established prognostic factors in endometrial cancer. <i>Anticancer Research</i> , 1996, 16, 947-9.	1.1	11
225	Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. <i>International Journal of Cancer</i> , 1995, 62, 126-131.	5.1	92
226	Serum evaluation of basic fibroblast growth factor in cervical cancer patients. <i>Cancer Letters</i> , 1995, 94, 227-231.	7.2	39
227	Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. <i>Anticancer Research</i> , 1995, 15, 1549-51.	1.1	40
228	Influence of Tumoral Microvessel Density on the Recurrence-Free Survival in Human Breast Cancer: Preliminary Results. <i>Oncology Research and Treatment</i> , 1994, 17, 44-49.	1.2	20
229	Thrombosis with paclitaxel. <i>Lancet</i> , The, 1994, 343, 727.	13.7	22
230	Vessel Invasion Predicts Early Recurrence in Breast Cancer: Preliminary Results. <i>Oncology Research and Treatment</i> , 1993, 16, 434-439.	1.2	0